2026-06-14T03:31:15Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/171432024-11-28T15:00:41Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Gavito, Ana Luisa
author
Bautista, Dolores
author
Suarez, Juan
author
Badran, Samir
author
Arco, Rocío
author
Pavón, Francisco-Javier
author
Serrano, Antonia
author
Rivera, Patricia
author
Decara, Juan
author
Cuesta, Antonio Luis
author
Rodríguez-de-Fonseca, Fernando
author
Baixeras, Elena
authoraffiliation
[Gavito,AL; Suarez,J; Arco,J; Pavón,FJ; Serrano,A; Rivera,P; Decara,J; Rodríguez-de-Fonseca,F; Baixera,E] Laboratorio de Investigación, IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, Málaga Spain. [Bautista,D] Unidad de Gestión Clínica de Anatomía Patológica, Hospital Regional Universitario de Málaga, Málaga, Spain. [Pavón,FJ] University College South Denmark, Esbjerg, Denmark. [Cuestya,AL] Danish Diabetes Academy, Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark.
2024-01-16T12:16:17Z
2024-01-16T12:16:17Z
2016-06-22
10.1371/journal.pone.0157956
1932-6203
PloS One
http://hdl.handle.net/10668/2399
27333268
http://hdl.handle.net/20.500.12105/17143
High-fat diet-induced obesity (DIO) is associated with fatty liver and elevated IL-6 circulating levels. IL-6 administration in rodents has yielded contradictory results regarding its effects on steatosis progression. In some models of fatty liver disease, high doses of human IL-6 ameliorate the liver steatosis, whereas restoration of IL-6 in DIO IL-6-/- mice up-regulates hepatic lipogenic enzymes and aggravates steatosis. We further examined the effects of chronic low doses of murine IL-6 on hepatic lipid metabolism in WT mice in DIO. IL-6 was delivered twice daily in C57BL/6J DIO mice for 15 days. The status and expression of IL-6-signalling mediators and targets were investigated in relation to the steatosis and lipid content in blood and in liver. IL-6 administration in DIO mice markedly raised circulating levels of lipids, glucose and leptin, elevated fat liver content and aggravated steatosis. Under IL-6 treatment there was hepatic Stat3 activation and increased gene expression of Socs3 and Tnf-alpha whereas the gene expression of endogenous IL-6, IL-6-receptor, Stat3, Cpt1 and the enzymes involved in lipogenesis was suppressed. These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.
eng
Animales
Alimentación rica en grasa
Hígado graso
Glucosa
Humanos
Interleucina-6
Leptina
Metabolismo lipídico
Lípidos
Lipogénesis
Ratones
Ratones consanguíneos C57BL
Ratones obesos
Obesidad
Ratas
Ratas Zucker
Receptores de interleucina-6
Factor de necrosis tumoral alfa
Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice.
research article